A Phase II multi-dosing study comparing potency between ARB-1740 and ARB-1467 study in HBV patients

Trial Profile

A Phase II multi-dosing study comparing potency between ARB-1740 and ARB-1467 study in HBV patients

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs ARB 1467 (Primary) ; ARB 1740 (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Aug 2017 According to an Arbutus Biopharma Corporation media release, the company is discontinuing development of ARB-1740.
    • 03 Aug 2017 According to an Arbutus Biopharma Corporation media release, status changed from recruiting to completed.
    • 10 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top